Open Orphan (LON: ORPH) is planning to demerge a non-core asset inherited from the merger with hVIVO and not even mentioned in the merger document published at the end of 2019. There are other non-core assets that could be worth even more.
Management of the contract research outfit wants to focus on the services business, and it plans to demerge the wholly owned development IP assets. The major asset is HVO-001, which is a small molecule, immunomodulator drug that could become a treatment for severe flu.
The last time hVIVO mentioned HVO-001 was in its announcement when it reported its ...
